NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
+0.84 (3.77%)
At close: May 24, 2024, 4:00 PM
+0.01 (0.04%)
After-hours: May 24, 2024, 7:35 PM EDT

Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.

The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NovoCure Limited
NovoCure logo
Country Jersey
Founded 2000
IPO Date Oct 2, 2015
Industry Medical Devices
Sector Healthcare
Employees 1,453
CEO Asaf Danziger

Contact Details

No. 4 The Forum, Grenville Street
St. Helier, Y9 JE2 4UF
Phone 44 (0)15 3475 6700

Stock Details

Ticker Symbol NVCR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001645113
CUSIP Number G6674U108
ISIN Number JE00BYSS4X48
SIC Code 3841

Key Executives

Name Position
William F. Doyle Executive Chairman
Asaf Danziger Chief Executive Officer and Director
Ashley Cordova Chief Financial Officer
Wilhelmus C. M. Groenhuysen Chief Operating Officer
Frank Leonard Executive Vice President and President of Novocure Oncology
Prof. Yoram Palti M.D., Ph.D. Founder and Chief Technology Officer
Dr. Moshe Giladi Ph.D. Chief Science Officer
Ingrid Goldberg Vice President of Investor Relations
Barak Ben Arye General Counsel
Michael Puri Chief Human Resources Officer

Latest SEC Filings

Date Type Title
May 20, 2024 8-K Current Report
May 2, 2024 10-Q Quarterly Report
May 2, 2024 8-K Current Report
Apr 22, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 22, 2024 DEF 14A Other definitive proxy statements
Apr 12, 2024 PRE 14A Other preliminary proxy statements
Mar 27, 2024 8-K Current Report
Mar 4, 2024 144 Filing
Mar 4, 2024 144 Filing
Mar 4, 2024 144 Filing